Company Overview
Nyrada is a drug discovery and development company, specialising in novel small molecule drugs to treat neurological and cardiovascular diseases. We are listed on the Australian Securities Exchange (ASX) under the ticker ASX:NYR.
Nyrada’s vision is to become a high growth pharmaceutical company specialising in drug discovery and early-stage drug development. Our drug development programs focus on areas of substantial unmet clinical need where few if any, effective or well-tolerated therapies exist.
Nyrada has two lead drug development programs:
Neuroprotection Program: a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischaemic stroke
Cardioprotection Program: A cardioprotectant drug to reduce the damage to the heart following myocardial infarction (heart attack).
